VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
ASSA ABLOY AB vs Gilead Sciences, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
ASSA ABLOY AB
ASSA-B · Nasdaq Stockholm
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into ASSA ABLOY AB's moat claims, evidence, and risks.
View ASSA-B analysisGilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisComparison highlights
- Moat score gap: ASSA ABLOY AB leads (76 / 100 vs 74 / 100 for Gilead Sciences, Inc.).
- Segment focus: ASSA ABLOY AB has 5 segments (32.9% in Entrance Systems); Gilead Sciences, Inc. has 5 segments (68.5% in HIV).
- Moat breadth: ASSA ABLOY AB has 4 moat types across 2 domains; Gilead Sciences, Inc. has 8 across 3.
Primary market context
ASSA ABLOY AB
Entrance Systems
Entrance automation and industrial door solutions (pedestrian automatic doors, industrial doors, loading dock equipment, service/maintenance)
Global
Commercial/industrial facilities via distributors, installers and service channels
OEM + service/maintenance provider
32.9%
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Side-by-side metrics
Moat coverage
Shared moat types
ASSA ABLOY AB strengths
Gilead Sciences, Inc. strengths
Segment mix
ASSA ABLOY AB segments
Full profile >Opening Solutions EMEIA
Oligopoly
Opening Solutions Americas
Oligopoly
Opening Solutions Asia Pacific
Competitive
Global Technologies
Oligopoly
Entrance Systems
Oligopoly
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.